Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers
Executive Summary
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.